NICE Rejects Novartis's Gilenya

by Dr. Trupti Shirole on  December 2, 2011 at 3:13 PM Drug News
RSS Email Print This Page Comment
National Institute for Health and Clinical Excellence (NICE), UK has failed to back the Novartis's multiple sclerosis pill Gilenya (Fingolimod) on the grounds that it is not a cost-effective treatment option. This means patients may only be able to take Gilenya if they have private medical insurance.
 NICE Rejects Novartis's Gilenya
NICE Rejects Novartis's Gilenya

Despite having offered discount, NICE estimated that the annual cost of the drug would stand around 19,196 pounds. While Novartis's competitor Biogen Idec's injectable Avonex costs 9,061 pounds

NICE's final decision is due in April. Till then Novartis has some time to either submit new data or revise its access scheme.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive